<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="publisher-id">pharmaceuticals</journal-id><journal-title-group><journal-title>Pharmaceuticals</journal-title></journal-title-group><issn pub-type="epub">1424-8247</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006033</article-id><article-id pub-id-type="pmc">PMC11859973</article-id><article-id pub-id-type="doi">10.3390/ph18020219</article-id><article-id pub-id-type="publisher-id">pharmaceuticals-18-00219</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Acetoacetate Ameliorates Hepatic Fibrosis by Targeting Peroxisome Proliferator-Activated Receptor Gamma to Restore Lipid Droplets in Activated Hepatic Stellate Cells</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Ya</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="fn1-pharmaceuticals-18-00219" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Feixia</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="fn1-pharmaceuticals-18-00219" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0001-2625-6667</contrib-id><name><surname>Hu</surname><given-names>Mengru</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role></contrib><contrib contrib-type="author"><name><surname>Xia</surname><given-names>Siwei</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Yang</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role></contrib><contrib contrib-type="author"><name><surname>Zheng</surname><given-names>Shizhong</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="c1-pharmaceuticals-18-00219" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Feng</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="c1-pharmaceuticals-18-00219" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Cozza</surname><given-names>Giorgio</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceuticals-18-00219">Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China; <email>20220821@njucm.edu.cn</email> (Y.Z.); <email>300585@njucm.edu.cn</email> (F.W.); <email>20230653@njucm.edu.cn</email> (M.H.); <email>20223116@njucm.edu.cn</email> (S.X.); <email>20200773@njucm.edu.cn</email> (Y.L.)</aff><author-notes><corresp id="c1-pharmaceuticals-18-00219"><label>*</label>Correspondence: <email>nytws@njucm.edu.cn</email> (S.Z.); <email>300631@njucm.edu.cn</email> (F.Z.)</corresp><fn id="fn1-pharmaceuticals-18-00219"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>06</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>18</volume><issue>2</issue><elocation-id>219</elocation-id><history><date date-type="received"><day>20</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>01</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>04</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background:</bold> Hepatic fibrosis (HF) is a progressive liver disease characterized by the activation of hepatic stellate cells (HSCs) and changes in lipid metabolism. Abnormal ketone body (KD) levels, including acetoacetate (AcAc) and beta-hydroxybutyrate (BHB), have been observed in patients with HF, but the mechanisms linking ketone metabolism to fibrosis progression remain unclear. <bold>Objectives:</bold> This study aimed to investigate the role of AcAc in modulating HSCs activation and its potential mechanisms in HF. <bold>Methods:</bold> We examined the effects of AcAc on HSCs activation by Western blot analysis and RT-PCR both in vivo and in vitro. The impact of AcAc on lipid droplet accumulation in HSCs was assessed using total cholesterol (TC), triglyceride (TG), and Retinol (RET) kits, along with Nile Red and Oil Red O staining. RT-PCR screening was performed to analyze the expression of genes involved in lipid droplet formation and lipid metabolism. <bold>Results:</bold> Our findings show that AcAc inhibited HSCs activation by restoring LD levels. Peroxisome Proliferator-Activated Receptor Gamma (PPAR&#x003b3;) was identified as a key regulator through gene screening. AcAc primarily regulated PPAR&#x003b3; expression, and knocking down PPAR&#x003b3; significantly aggravated HF progression. <bold>Conclusions:</bold> The ability of AcAc to restore LD levels and regulate PPAR&#x003b3; suggests that it may represent a promising therapeutic strategy for HF by inhibiting HSCs activation.</p></abstract><kwd-group><kwd>hepatic fibrosis</kwd><kwd>acetoacetate</kwd><kwd>PPAR&#x003b3;</kwd><kwd>lipid droplets</kwd></kwd-group><funding-group><award-group><funding-source>National Natural Science Foundation of China</funding-source><award-id>82173874</award-id><award-id>82073914</award-id><award-id>82304595</award-id></award-group><award-group><funding-source>Natural Science Foundation of Jiangsu Province of China</funding-source><award-id>BK20230458</award-id></award-group><award-group><funding-source>Natural Science Foundation of the Jiangsu Higher Education Institutions of China</funding-source><award-id>23KJB310017</award-id></award-group><award-group><funding-source>Qing Lan Project of Jiangsu Higher Institutions (Young and Middle-Aged Academic Leader)</funding-source></award-group><funding-statement>This work was financially supported by the National Natural Science Foundation of China (82173874, 82073914, 82304595), the Natural Science Foundation of Jiangsu Province of China (BK20230458), the Natural Science Foundation of the Jiangsu Higher Education Institutions of China (23KJB310017), the Qing Lan Project of Jiangsu Higher Institutions (Young and Middle-Aged Academic Leader).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceuticals-18-00219"><title>1. Introduction</title><p>Hepatic fibrosis (HF) is a pathological change caused by chronic liver injury leading to excessive deposition of extracellular matrix (ECM), and its mechanism of occurrence is related to endothelial cell injury, inflammatory immune cell activation, and hepatic stellate cells (HSCs) activation [<xref rid="B1-pharmaceuticals-18-00219" ref-type="bibr">1</xref>]. It plays a crucial role in the progression of chronic liver disease to cirrhosis and eventually to hepatocellular carcinoma [<xref rid="B2-pharmaceuticals-18-00219" ref-type="bibr">2</xref>]. Common etiologic factors include viral hepatitis, alcoholic liver disease, nonalcoholic fatty liver disease, drug toxicity, and autoimmune diseases [<xref rid="B3-pharmaceuticals-18-00219" ref-type="bibr">3</xref>,<xref rid="B4-pharmaceuticals-18-00219" ref-type="bibr">4</xref>]. The pathophysiologic process of HF involves multiple cell types and molecular mechanisms, with HSCs playing a key role in the development of fibrosis [<xref rid="B4-pharmaceuticals-18-00219" ref-type="bibr">4</xref>]. Under normal conditions, HSCs exhibit a quiescent phenotype [<xref rid="B5-pharmaceuticals-18-00219" ref-type="bibr">5</xref>]. When stimulated by hepatic injury and inflammatory responses, HSCs transform from a quiescent to a highly proliferative and contractile myofibroblast phenotype, secreting large amounts of ECM proteins, releasing a series of pro-inflammatory factors (e.g., IL-6, etc.) and pro-fibrotic factors (e.g., TGF-&#x003b2;1) [<xref rid="B6-pharmaceuticals-18-00219" ref-type="bibr">6</xref>], overexpressing &#x003b1;-SMA, fibronectin, collagen and other proteins, which promote the progression of HF [<xref rid="B7-pharmaceuticals-18-00219" ref-type="bibr">7</xref>]. Therefore, activated HSCs have been regarded as a major target for the treatment of HF.</p><p>Lipid droplets (LDs), as the main form of intracellular lipid storage, play an important role in the metabolic regulation of HSCs [<xref rid="B8-pharmaceuticals-18-00219" ref-type="bibr">8</xref>]. It was found that the release of LDs containing retinyl esters and triglyceride is a defining feature of HSC activation, and that quiescent HSCs cytoplasm is enriched in vitamin A lipid droplets, which, when activated, have a reduced capacity to store vitamin A, leading to a decrease in lipid droplet content in HSCs [<xref rid="B9-pharmaceuticals-18-00219" ref-type="bibr">9</xref>], and our previous study also demonstrated that inhibition of lipid droplet autophagy ameliorates HF by increasing lipid content in HSCs [<xref rid="B10-pharmaceuticals-18-00219" ref-type="bibr">10</xref>]. Changes in intracellular lipid droplet content are mainly influenced by the conjugation or metabolism of lipid droplets [<xref rid="B11-pharmaceuticals-18-00219" ref-type="bibr">11</xref>]. PPAR&#x003b3;, a key factor in the synthesis of LDs, has been shown to be closely associated with HF, but its molecular mechanism is still unclear [<xref rid="B12-pharmaceuticals-18-00219" ref-type="bibr">12</xref>,<xref rid="B13-pharmaceuticals-18-00219" ref-type="bibr">13</xref>].</p><p>As an important metabolic organ, the liver is involved in various material and energy metabolic processes [<xref rid="B14-pharmaceuticals-18-00219" ref-type="bibr">14</xref>]. Therefore, studying the pathogenesis of HF from the perspective of metabolic regulation is expected to provide new drug targets for HF and promote the development of safe and efficient antifibrotic drugs. Ketone body metabolism is a metabolic process carried out exclusively in the mitochondria of hepatocytes, which mainly includes acetoacetate (AcAc), &#x003b2;-hydroxybutyrate (BHB), and trace amounts of acetone [<xref rid="B15-pharmaceuticals-18-00219" ref-type="bibr">15</xref>]. AcAc is a naturally occurring metabolite produced by the liver that provides cellular energy through conversion to acetyl-CoA. It also involves conversion to other metabolites, including acetone and acetoacetate derivatives, which are ultimately excreted in the urine or exhaled [<xref rid="B16-pharmaceuticals-18-00219" ref-type="bibr">16</xref>]. Dysregulation of ketone body metabolism is closely associated with the development of several diseases [<xref rid="B17-pharmaceuticals-18-00219" ref-type="bibr">17</xref>,<xref rid="B18-pharmaceuticals-18-00219" ref-type="bibr">18</xref>]. A study has shown that targeting 3-oxoacid CoA-transferase 1 (OXCT1) to regulate ketone body metabolism in macrophages helps to reduce the depletion of CD8+ T cells, which in turn maintains their anti-tumor function and enhances immune responses [<xref rid="B17-pharmaceuticals-18-00219" ref-type="bibr">17</xref>]. In addition, the injection of AcAc was able to prevent the deposition of ECM in HF mice, suggesting that this pathway may play a role in HF; however, the exact mechanism of action is not clear [<xref rid="B18-pharmaceuticals-18-00219" ref-type="bibr">18</xref>]. Therefore, the aim of this study was to explore the mechanisms of ketone bodies AcAc and BHB in regulating HSCs activation and lipid droplet synthesis to further understand the role of ketone bodies in HF.</p></sec><sec sec-type="results" id="sec2-pharmaceuticals-18-00219"><title>2. Results</title><sec id="sec2dot1-pharmaceuticals-18-00219"><title>2.1. The Ketone Body Acetoacetate (AcAc) but Not Beta-Hydroxybutyrate (BHB) Inhibits Hepatic Stellate Cells (HSCs) Activation</title><p>Ketone bodies are composed of acetoacetic acid (AcAc), beta-hydroxybutyric acid (BHB), and acetone [<xref rid="B15-pharmaceuticals-18-00219" ref-type="bibr">15</xref>]. Since acetone has a low concentration in the blood and is mainly exhaled rather than directly utilized by cells, its metabolism in vivo is limited and therefore less of a major focus of research. Therefore, the present study focused on the role of AcAc and BHB. In order to investigate the direct effects of AcAc and BHB on hepatic stellate cells, we cultured the HSC cell line LX-2 cells, and LX-2 was treated with AcAc and BHB selected according to the available literature (0&#x02013;40 mM) for 24 h [<xref rid="B19-pharmaceuticals-18-00219" ref-type="bibr">19</xref>]. The results of MTT assay showed that 2 mM of AcAc and 1 mM of BHB significantly reduced cell viability, and in order to select the concentration of drug treatments more accurately, we further calculated the IC<sub>50</sub> values of the two, which were AcAc = 25.24 mM and BHB = 23.51 mM, respectively. Then, in order to rule out the toxicity effect of the drugs on the cells, we chose 1 mM, 2 mM, 5 mM, and 10 mM for the experiments (<xref rid="pharmaceuticals-18-00219-f001" ref-type="fig">Figure 1</xref>A,B). &#x003b1;-SMA and fibronectin are markers of HSCs activation, and both reflect the progression of HF, which are important biomarkers for assessing HF. Therefore, we further analyzed the mRNA and protein expression of &#x003b1;-SMA and fibronectin by RT-qPCR and Western blot analysis after AcAc and BHB treatments, which found that AcAc was able to reduce the expression of &#x003b1;-SMA and fibronectin concentration-dependently, whereas BHB had the opposite effect. The results presented above demonstrated that AcAc significantly inhibited the activation of hematopoietic stem cells, whereas BHB did not exhibit such an effect (<xref rid="pharmaceuticals-18-00219-f001" ref-type="fig">Figure 1</xref>C&#x02013;F).</p></sec><sec id="sec2dot2-pharmaceuticals-18-00219"><title>2.2. Acetoacetate (AcAc) Alleviated Hepatic Fibrosis (HF)</title><p>To further verify the consistency of the in vivo and in vitro results, we first induced HF in mice with CCl<sub>4</sub> for 4 weeks to establish an HF model. The mice were subsequently injected with AcAc (50 mg/kg) or BHB (50 mg/kg) for 3 weeks while continuing CCl<sub>4</sub> induction. The selected doses of 50 mg/kg for both AcAc and BHB were based on a comprehensive evaluation of several factors, including the pharmacokinetics of the drugs, differences in mouse strains, the objectives of the experiment, and safety considerations, as well as previous studies in the literature [<xref rid="B19-pharmaceuticals-18-00219" ref-type="bibr">19</xref>]. H&#x00026;E, Masson, and Sirius Red staining showed that CCl<sub>4</sub>-treated mice developed typical HF, which was significantly attenuated by AcAc, whereas BHB did not (<xref rid="pharmaceuticals-18-00219-f002" ref-type="fig">Figure 2</xref>A). Further serum analysis showed that AcAc had a stronger protective effect against liver injury and HF in vivo (<xref rid="pharmaceuticals-18-00219-f002" ref-type="fig">Figure 2</xref>B). Subsequently, we extracted proteins from mouse liver tissues and assessed the protein expression of &#x003b1;-SMA and fibronectin (markers of hepatic stellate cells activation) by Western blot analysis. The results showed that AcAc significantly inhibited the expression of HF-related proteins, whereas BHB did not (<xref rid="pharmaceuticals-18-00219-f002" ref-type="fig">Figure 2</xref>C).</p></sec><sec id="sec2dot3-pharmaceuticals-18-00219"><title>2.3. Acetoacetate (AcAc) Increased the Content of Lipid Droplets in Hepatic Stellate Cells (HSCs)</title><p>Lipid droplets (LDs) play a crucial role in maintaining the quiescent state of HSCs. Previous studies have shown that the absence of lipid droplets induces HSCs activation, whereas the restoration of lipid droplets facilitates the shift of activated HSCs back to the resting state [<xref rid="B10-pharmaceuticals-18-00219" ref-type="bibr">10</xref>]. Therefore, we aimed to investigate the effect of AcAc on the lipid droplet content of HSCs. As demonstrated by Oil Red O and Nile Red staining, we found that AcAc significantly increased the accumulation of lipid droplets in LX-2 cells (<xref rid="pharmaceuticals-18-00219-f003" ref-type="fig">Figure 3</xref>A). Similarly, we further examined the lipid droplet content in AcAc-treated cells using total cholesterol (TC), triglyceride (TG), and Retinol (RET) assay kits, respectively. The results also confirmed that AcAc was able to concentration-dependently increase the levels of the major contents of lipid droplets in LX-2 cells (<xref rid="pharmaceuticals-18-00219-f003" ref-type="fig">Figure 3</xref>B&#x02013;D). Lipid droplet metabolism includes the processes of lipogenesis, fatty acid oxidation, fatty acid uptake, and lipid droplet autophagy [<xref rid="B20-pharmaceuticals-18-00219" ref-type="bibr">20</xref>]. We queried the key enzymes involved in lipid droplet metabolism processes through a large body of literature, and the roles of acetyl-CoA acetyltransferase (ACACa), fatty acid synthase (FASN), and sterol regulatory element-binding protein 1 (SREBP1) have extensive validation in lipid synthesis [<xref rid="B21-pharmaceuticals-18-00219" ref-type="bibr">21</xref>], while carnitine palmitoyltransferase 1 (CPT1), acyl-CoA oxidase 1 (ACOX1), and medium-chain acyl-CoA dehydrogenase (MCAD) have been shown to play a role in the oxidation of fatty acids [<xref rid="B22-pharmaceuticals-18-00219" ref-type="bibr">22</xref>]. Fatty acid uptake is accomplished through transporter proteins such as fatty acid transport protein 1 (FATP1) and cluster of differentiation 36 (CD36) [<xref rid="B23-pharmaceuticals-18-00219" ref-type="bibr">23</xref>], while proteins such as perilipin 2 (PLIN2), Ras-related protein rab-7 (RAB7), and autophagy-related protein 2A (ATG2A) regulate the degradation of lipid droplets through mechanisms associated with autophagy [<xref rid="B24-pharmaceuticals-18-00219" ref-type="bibr">24</xref>,<xref rid="B25-pharmaceuticals-18-00219" ref-type="bibr">25</xref>]. We further investigated the effect of AcAc on key proteins involved in lipid droplet metabolism using RT-qPCR. The results indicated that AcAc had minimal impact on the oxidation and uptake phases of lipid droplets. Interestingly, AcAc significantly affected the expression of PPAR&#x003b3;, a critical gene in lipid droplet formation. Additionally, we observed that AcAc increased the expression of PLIN2, an autophagy-related gene. This increase may be attributed to the dual role of PLIN2: it is involved in intracellular lipid droplet formation through chaperone-mediated autophagy (CMA) degradation and plays a key regulatory role in lipid droplet stabilization and storage [<xref rid="B26-pharmaceuticals-18-00219" ref-type="bibr">26</xref>] (<xref rid="pharmaceuticals-18-00219-f003" ref-type="fig">Figure 3</xref>E). Based on these results, we hypothesized that AcAc may promote the recovery of lipid droplets in activated HSCs by upregulating the expression of PPAR&#x003b3;.</p></sec><sec id="sec2dot4-pharmaceuticals-18-00219"><title>2.4. Interference of Peroxisome Proliferator-Activated Receptor Gamma (PPAR&#x003b3;) Reversed the Inhibition of Hepatic Stellate Cells (HSCs) Activation by Acetoacetate (AcAc)</title><p>To further investigate the effect of AcAc on PPAR&#x003b3;, we examined the protein expression of PPAR&#x003b3; after the AcAc treatment by Western blot analysis and found that AcAc significantly increased the protein expression of PPAR&#x003b3; (<xref rid="pharmaceuticals-18-00219-f004" ref-type="fig">Figure 4</xref>A). Next, to demonstrate the important role of PPAR&#x003b3; in the inhibition of hepatic stellate cells activation by AcAc, we used LX-2 cells transfected with siPPAR&#x003b3; to investigate whether it directly affected hepatic stellate cells activation. We detected the interference efficiency of PPAR&#x003b3; by RT-qPCR and Western blot analysis, respectively, and found that small interfering RNA transfection successfully reduced the mRNA and protein expression of PPAR&#x003b3; in LX-2 cells (<xref rid="pharmaceuticals-18-00219-f004" ref-type="fig">Figure 4</xref>B,C). Therefore, we further experimented and found that the effects of AcAc on &#x003b1;-SMA and fibronectin were suppressed when PPAR&#x003b3; was interfered (<xref rid="pharmaceuticals-18-00219-f004" ref-type="fig">Figure 4</xref>D,E). In addition, PPAR&#x003b3; interference also reversed AcAc-induced lipid droplet accumulation, specifically, PPAR&#x003b3; interference significantly reversed the increase in lipid droplet content in AcAc-treated LX-2 cells (<xref rid="pharmaceuticals-18-00219-f004" ref-type="fig">Figure 4</xref>F) and limited the elevation of TC, TG, and RET levels (<xref rid="pharmaceuticals-18-00219-f004" ref-type="fig">Figure 4</xref>G&#x02013;H). This suggests that AcAc affects the formation of lipid droplets and the levels of related metabolites by regulating the expression of PPAR&#x003b3;. The above results suggest that PPAR&#x003b3; is an important target of AcAc to inhibit HSCs activation.</p></sec><sec id="sec2dot5-pharmaceuticals-18-00219"><title>2.5. Interference of Peroxisome Proliferator-Activated Receptor Gamma (PPAR&#x003b3;) Reversed the Anti-Fibrotic Effect of Acetoacetate (AcAc)</title><p>To investigate whether AcAc regulates and attenuates HF through the PPAR&#x003b3;, we used mice for intraperitoneal injection of AcAc (50 mg/kg) for 4 weeks and VA-Lip-shRNA-PPAR&#x003b3; was prepared according to a standard reported method and was administered into CCl<sub>4</sub>-challenged mice through the tail vein to reduce the expression of PPAR&#x003b3; [<xref rid="B27-pharmaceuticals-18-00219" ref-type="bibr">27</xref>]. Histological analyses by H&#x00026;E staining, Masson staining, and Sirius Red staining showed that AcAc treatment significantly improved the liver organization and reduced the manifestation of CCl<sub>4</sub>-induced liver injury and fibrosis. However, when PPAR&#x003b3; was interfered, this protective effect was significantly reversed, and the liver showed renewed damage to its tissue structure and increased fibrosis and inflammation (<xref rid="pharmaceuticals-18-00219-f005" ref-type="fig">Figure 5</xref>A). Further analysis of the biochemical indices of serum and liver tissue showed that AcAc treatment significantly reduced markers related to HF and liver injury compared with the CCl<sub>4</sub>-treated group; however, the improvement of these indices was significantly attenuated or completely disappeared after PPAR&#x003b3; interference, suggesting that the interference of PPAR&#x003b3; reversed the anti-fibrotic effect of AcAc (<xref rid="pharmaceuticals-18-00219-f005" ref-type="fig">Figure 5</xref>B). To further verify the critical role of PPAR&#x003b3; in the anti-fibrotic effect of AcAc, the protein expression related to fibrosis was analyzed by Western blot analysis. The results showed that AcAc was able to significantly down-regulate the expression of fibronectin and &#x003b1;-SMA, while up-regulating the level of PPAR&#x003b3;, suggesting that AcAc inhibited hepatic fibrosis by activating PPAR&#x003b3;. However, under the condition of PPAR&#x003b3; interference, the regulatory effect of AcAc on these proteins was significantly weakened, the levels of fibronectin and &#x003b1;-SMA failed to be effectively decreased, and the up-regulatory effect of PPAR&#x003b3; was not maintained (<xref rid="pharmaceuticals-18-00219-f005" ref-type="fig">Figure 5</xref>C). Taken together, the above experimental results indicate that PPAR&#x003b3; is a key target of the anti-HF effect of AcAc, and the interference of PPAR&#x003b3; can significantly reverse the protective effect of AcAc in alleviating HF. These data reveal the important role of PPAR&#x003b3; in the regulation of HF by AcAc and provide new perspectives for future therapeutic strategies of HF.</p></sec></sec><sec sec-type="discussion" id="sec3-pharmaceuticals-18-00219"><title>3. Discussion</title><p>Hepatic stellate cells play a crucial role in the onset and progression of HF [<xref rid="B1-pharmaceuticals-18-00219" ref-type="bibr">1</xref>,<xref rid="B28-pharmaceuticals-18-00219" ref-type="bibr">28</xref>]. HSCs have an important function in the maintenance of homeostasis in the liver, typically storing vitamin A and maintaining their resting state via LDs [<xref rid="B28-pharmaceuticals-18-00219" ref-type="bibr">28</xref>]. In response to liver injury, HSCs are activated and transformed into myofibroblasts that secrete large amounts of collagen and other extracellular matrix components, thereby driving HF [<xref rid="B6-pharmaceuticals-18-00219" ref-type="bibr">6</xref>], thus exploring the mechanisms that inhibit the activation of HSCs is critical for the development of effective therapeutic strategies for HF.</p><p>PPAR&#x003b3; is a member of the nuclear receptor superfamily, which mainly regulates physiological processes such as lipid metabolism, insulin sensitivity, and inflammatory response [<xref rid="B29-pharmaceuticals-18-00219" ref-type="bibr">29</xref>]. It has been found that PPAR&#x003b3; is not only involved in the regulation of lipid metabolism, but also plays a key role in the immune response and fibrotic process in many diseases [<xref rid="B30-pharmaceuticals-18-00219" ref-type="bibr">30</xref>]. In studies of HF, PPAR&#x003b3; has been shown to have the potential to inhibit the activation of HSCs and attenuate HF [<xref rid="B12-pharmaceuticals-18-00219" ref-type="bibr">12</xref>,<xref rid="B13-pharmaceuticals-18-00219" ref-type="bibr">13</xref>]. PPAR&#x003b3; activates the transcription of downstream genes by binding to its ligands, which in turn regulates biological processes such as lipid droplet production, fatty acid metabolism, and autophagy [<xref rid="B31-pharmaceuticals-18-00219" ref-type="bibr">31</xref>], which may have an impact on the activation of HSCs and the development of HF.</p><p>In this study, we revealed the critical role of PPAR&#x003b3; in HF by exploring the effects of AcAc on HSCs. Our data showed that the ketone body AcAc significantly inhibited the activation of HSCs and HF, whereas BHB did not show a similar effect. In vitro experiments, AcAc decreased the expression of &#x003b1;-SMA and fibronectin, markers of HSCs activation, in a concentration-dependent manner and promoted the maintenance of HSCs quiescence by increasing the accumulation of LDs. AcAc inhibited HSCs activation by upregulating the expression of PPAR&#x003b3;, which promotes the generation of LDs and affects the levels of related metabolites. Further in vivo experiments demonstrated that AcAc significantly attenuated the manifestation of liver injury and fibrosis in a mouse model of CCl<sub>4</sub>-induced HF. AcAc suppressed the expression of HF-associated proteins by regulating PPAR&#x003b3;. However, the interference of PPAR&#x003b3; significantly reversed the anti-fibrotic effect of AcAc, suggesting that PPAR&#x003b3; is a key target of the anti-HF effect of AcAc. In summary, AcAc inhibited HSCs activation and HF by activating the PPAR&#x003b3;, and PPAR&#x003b3; interference significantly reversed this effect, suggesting an important role of PPAR&#x003b3; in AcAc regulation of HF. Due to the important role of AcAc in energy metabolism and its short half-life, its degradation does not significantly reduce its effect in inhibiting HSCs activation. This study provides new perspectives for future therapeutic strategies for HF, especially by regulating PPAR&#x003b3; expression.</p></sec><sec id="sec4-pharmaceuticals-18-00219"><title>4. Materials and Methods</title><sec id="sec4dot1-pharmaceuticals-18-00219"><title>4.1. Chemical Reagents</title><p>In vitro reagents: &#x003b2;-hydroxybutyric acid (Cat#HY-113378) was purchased from MedChemExpress (Shanghai, China). Lithium acetoacetate (Cat#3483-11-2) was purchased from Sigma-Aldrich (St. Louis, MI, USA). Primary antibodies against &#x003b1;-SMA (ab32575) and fibronectin (ab2413) were purchased from Abcam Technology (Cambridge, MA, USA). The Proteintech Group (Chicago, IL, USA) supplied the primary antibodies for PPAR&#x003b3; (16643-AP), &#x003b2;-Actin (66009-1-AP), and anti-rabbit IgG (SA00001-2).</p><p>In vivo reagents: Acetoacetate (Cat#E808776) was purchased from Mclean (Shanghai, China). Sodium &#x003b2;-hydroxybutyrate (Cat#298360) was obtained from Sigma-Aldrich (St. Louis, MI, USA).</p></sec><sec id="sec4dot2-pharmaceuticals-18-00219"><title>4.2. Animal Experiments</title><p>The study protocols were sanctioned by the Animal Care and Use Committee of Nanjing University of Chinese Medicine (approval number: 202305A038, Nanjing, China). Male ICR mice, weighing about 18&#x02013;22 g, were obtained from Hangzhou Medical College. The environment was controlled with a 12-h light/dark cycle, at 22 &#x000b0;C temperature and 40&#x02013;60% humidity. Following a 7-day acclimation period, HF was induced via intraperitoneal injection of a CCl<sub>4</sub> and olive oil mixture (1:9 <italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>; 0.5 mL/100 g). ShRNA of mouse PPAR&#x003b3; (5&#x02032;-GCCCTGGCAAAGCATTTGTAT-3&#x02032;) was synthesized by Nanjing Jin Ting biological science and technology (Nanjing, China). VA-Lip refers to liposomes that are bound with vitamin A, which are used for targeted delivery of the compound. VA-Lip-shRNA-PPAR&#x003b3; was prepared according to a standard reported method and was administered into CCl<sub>4</sub>-challenged mice through the tail vein [<xref rid="B27-pharmaceuticals-18-00219" ref-type="bibr">27</xref>]. Forty-two mice were randomly assigned to seven groups: Control, CCl<sub>4</sub>, CCl<sub>4</sub>+AcAc (50 mg/kg), CCl<sub>4</sub>+&#x003b2;-hydroxybutyrate (50 mg/kg), CCl<sub>4</sub>+VA-Ctrl shRNA, CCl<sub>4</sub>+VA-PPAR&#x003b3; shRNA, CCl<sub>4</sub>+VA-PPAR&#x003b3; shRNA+AcAc. Except for the control group, the other mice received intraperitoneal injections of the CCl<sub>4</sub> and olive oil mixture three times a week for eight weeks. After eight weeks, the mice were anesthetized by a 2-min inhalation of isoflurane at a concentration of around 1&#x02013;1.5%, and blood was collected from their orbits. One portion of the mouse liver was fixed in paraformaldehyde, while the other portion was immediately stored in the &#x02212;80 &#x000b0;C freezer.</p></sec><sec id="sec4dot3-pharmaceuticals-18-00219"><title>4.3. Cell Culture and Transfection</title><p>LX-2 cells (a human HSCs line) were obtained from Chemical Book, Shanghai, China. These cells were cultured in Dulbecco&#x02019;s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS). Lipofectamine 2000 (Life Technologies Corporation, Carlsbad, CA, USA) was used to transfect siPPAR&#x003b3; plasmids into LX-2 cells according to the manufacturer&#x02019;s instructions.</p></sec><sec id="sec4dot4-pharmaceuticals-18-00219"><title>4.4. Quantitative Real-Time PCR (RT-qPCR)</title><p>RNA extraction was performed on LX-2 cells. Next, ABScript II RT Master Mix was used to reverse-transcribe the RNA into cDNA. SYBR Green PCR Fast qPCR Mix (2&#x000d7;, Abclonal, Wuhan, China) was used to amplify cDNA. The mRNA levels of the target genes were determined and normalized to the control gene, GAPDH. Each set of data was independently replicated 3 times. Primer sequences are provided in <xref rid="pharmaceuticals-18-00219-t001" ref-type="table">Table 1</xref>.</p></sec><sec id="sec4dot5-pharmaceuticals-18-00219"><title>4.5. Western Blotting</title><p>Liver or cell lysates were prepared using a RIPA buffer containing protease inhibitors. Tissues or cells were homogenized in a RIPA buffer supplemented with phosphatase inhibitors and protease inhibitors (PMSFs) at a 100:1:1 ratio to minimize protein degradation. Protein concentrations were determined using a NanoDrop spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). For Western blot analysis, 50 &#x003bc;g of protein from each sample was loaded onto a 12% polyacrylamide gel for electrophoresis (the gel concentration was adjusted as needed for each experiment). Following electrophoresis, proteins were transferred to a polyvinylidene fluoride (PVDF) membrane, which was subsequently blocked and incubated with the appropriate primary antibody. Protein bands were visualized using enhanced chemiluminescence and quantified. Each experiment was performed with three independent biological replicates. All antibodies used in the study are listed in <xref rid="pharmaceuticals-18-00219-t002" ref-type="table">Table 2</xref>.</p></sec><sec id="sec4dot6-pharmaceuticals-18-00219"><title>4.6. Oil Red O Staining and Nile Red Staining</title><p>Oil Red O staining was performed using the KeyGEN kit (KGA329, KeyGEN, Nanjing, China). After preparing the Oil Red O solution, samples were incubated in it for 15 min. Afterward, LX-2 cells were stained with hematoxylin and slide-mounted. For Nile Red staining (KGDYE22190, KeyGEN), Nile Red was dissolved in DMSO to a concentration of 5 mg/mL. The Nile Red solution was then diluted 1:100 with DMEM medium and applied to a 24-well plate. LX-2 cells were incubated with the Nile Red solution for 10 min at 37 &#x000b0;C, followed by fixation with 4% paraformaldehyde for 30 min. Subsequently, LX-2 cells were incubated with DAPI Dye Solution (KGA215, KeyGEN) for 2 min. All images were captured using a ZEISS Axiovert A1 fluorescence microscope (ZEISS, Baden-W&#x000fc;rttemberg, Germany). Each set of data was independently replicated 3 times. Representative images showed Oil Red O and Nile Red staining of lipid droplets (100&#x000d7; magnification, scale bar = 20 &#x003bc;m).</p></sec><sec id="sec4dot7-pharmaceuticals-18-00219"><title>4.7. Cell Viability Assay</title><p>LX-2 cells were harvested and seeded into two 96-well plates at a density of approximately 50&#x02013;60%. Six replicates were set up for each group. The plates were incubated at 37 &#x000b0;C in a 5% CO<sub>2</sub> atmosphere for 24 h. The following day, the cells were treated with different concentrations (0&#x02013;40 mM) of AcAc and BHB, respectively. For the control group, DMSO, which was used to dissolve AcAc and BHB, was added. The cells were then incubated for another 24 h. On the third day, 20 &#x000b5;L of MTT solution (5 mg/mL, 0.5%) was added to each well, and the cells were incubated with the MTT solution for 4 h to allow for the reduction in MTT by metabolically active cells, forming purple formazan crystals. After the incubation, 150 &#x000b5;L of DMSO was added to each well to dissolve the formazan crystals. The absorbance of each well was measured at 490 nm using a Multi-Detection Microplate Reader (Bio-Rad, Hercules, CA, USA). Cell viability was assessed based on the absorbance values.</p></sec><sec id="sec4dot8-pharmaceuticals-18-00219"><title>4.8. Biochemical Analysis and Enzyme Linked Immunosorbent Assay</title><p>The Retinol (RET) content in LX-2 cells was detected using the RET ELISA kit (YFXEH01860, Yeasen Biotechnology, Shanghai, China). Total cholesterol (TC) and triglyceride (TG) levels in LX-2 cells were measured using the Total Cholesterol Test Kit (A030-2-1) and the Triglyceride Test Kit (A110-2-1). The experiments and data analysis were performed according to the kit instructions. Additionally, blood samples were obtained from mouse orbital veins and allowed to stand at room temperature for 2 h before being centrifuged at 3000 rpm and 4 &#x000b0;C for 30 min. Markers of liver injury and HF: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), procollagen III (PC-III), hyaluronic acid (HA), laminin (LN), and collagen type IV (IV-C) were analyzed using commercial ELISA kits provided by Nanjing Jinting Biotechnology (Nanjing, China).</p></sec><sec id="sec4dot9-pharmaceuticals-18-00219"><title>4.9. Histological Analysis</title><p>Tissue samples were sectioned and fixed in 10% neutral buffered formalin. These fixed tissues were then dehydrated and embedded in paraffin, preparing sections 4&#x02013;6 microns thick. To assess liver morphology and the extent of fibrosis, hematoxylin and eosin (H&#x00026;E), Masson, and Sirius Red staining were performed. Microscopic images of these stained sections were captured at random using a Zeiss Axio Vert. A1 microscope (ZEISS, Baden-W&#x000fc;rttemberg, Germany) and a magnification of &#x000d7;400.</p></sec><sec id="sec4dot10-pharmaceuticals-18-00219"><title>4.10. Statistical Analysis</title><p>Data are presented as mean &#x000b1; standard error of the mean (SEM). A Student&#x02019;s <italic toggle="yes">t</italic>-test was used for comparisons between two groups. One-way and multi-way ANOVA were used to compare more than two groups. Bars represent mean &#x000b1; SEM. * <italic toggle="yes">p</italic> &#x0003c; 0.05, ** <italic toggle="yes">p</italic> &#x0003c; 0.01, *** <italic toggle="yes">p</italic> &#x0003c; 0.001, **** <italic toggle="yes">p</italic> &#x0003c; 0.0001, <sup>#</sup>
<italic toggle="yes">p</italic> &#x0003c; 0.05, <sup>##</sup>
<italic toggle="yes">p</italic> &#x0003c; 0.01, <sup>###</sup>
<italic toggle="yes">p</italic> &#x0003c; 0.001.</p></sec></sec><sec sec-type="conclusions" id="sec5-pharmaceuticals-18-00219"><title>5. Conclusions</title><p>In summary, our findings provide the first evidence that AcAc inhibits HSCs activation and HF by regulating PPAR&#x003b3;. Future studies need to delve into the role of PPAR&#x003b3; in HF as well as the mechanism of AcAc regulation of PPAR&#x003b3;, which will provide a solid foundation for the prevention and treatment of HF.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Validation, conceptualization, and methodology, Y.Z. and F.W.; analysis of formal documents, cultivating data, M.H., S.X. and Y.L.; acquisition of funding, F.W., F.Z. and S.Z.; the original draft of the writing, Y.Z.; editing and reviewing, Y.Z. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The study protocols were sanctioned by the Animal Care and Use Committee of Nanjing University of Chinese Medicine (approval number: 202305A038, Nanjing, China).</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><glossary><title>Abbreviations</title><p>The following abbreviations are used in this manuscript:
<array><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">HF</td><td align="left" valign="middle" rowspan="1" colspan="1">Hepatic fibrosis</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HSCs</td><td align="left" valign="middle" rowspan="1" colspan="1">Hepatic stellate cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ECM</td><td align="left" valign="middle" rowspan="1" colspan="1">Extracellular matrix</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x003b1;-SMA</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x003b1;-smooth muscle actin</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">KD</td><td align="left" valign="middle" rowspan="1" colspan="1">Ketone body</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AcAc</td><td align="left" valign="middle" rowspan="1" colspan="1">Acetoacetate</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BHB</td><td align="left" valign="middle" rowspan="1" colspan="1">beta-hydroxybutyric acid</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LDs</td><td align="left" valign="middle" rowspan="1" colspan="1">lipid droplets</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TG</td><td align="left" valign="middle" rowspan="1" colspan="1">Triglyceride</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TC</td><td align="left" valign="middle" rowspan="1" colspan="1">Total Cholesterol</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">RET</td><td align="left" valign="middle" rowspan="1" colspan="1">Retinol</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PPAR&#x003b3;</td><td align="left" valign="middle" rowspan="1" colspan="1">Peroxisome proliferator-activated receptor &#x003b3;</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OXCT1</td><td align="left" valign="middle" rowspan="1" colspan="1">3-oxoacid CoA-transferase 1 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ACACa</td><td align="left" valign="middle" rowspan="1" colspan="1">Acetyl-CoA Acetyltransferase 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">FASN</td><td align="left" valign="middle" rowspan="1" colspan="1">Fatty Acid Synthase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SREBP1</td><td align="left" valign="middle" rowspan="1" colspan="1">Sterol Regulatory Element-Binding Protein 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CPT1</td><td align="left" valign="middle" rowspan="1" colspan="1">Carnitine Palmitoyltransferase 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ACOX1</td><td align="left" valign="middle" rowspan="1" colspan="1">Acyl-CoA Oxidase 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MCAD</td><td align="left" valign="middle" rowspan="1" colspan="1">Medium-Chain Acyl-CoA Dehydrogenase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">FATP1</td><td align="left" valign="middle" rowspan="1" colspan="1">Fatty Acid Transport Protein 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CD36</td><td align="left" valign="middle" rowspan="1" colspan="1">Cluster of Differentiation 36</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PLIN2</td><td align="left" valign="middle" rowspan="1" colspan="1">Perilipin 2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">RAB7</td><td align="left" valign="middle" rowspan="1" colspan="1">RAB7&#x02014;Ras-Related Protein Rab-7</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ATG2A</td><td align="left" valign="middle" rowspan="1" colspan="1">Autophagy-Related Protein 2A</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CMA</td><td align="left" valign="middle" rowspan="1" colspan="1">Chaperone mediated autophagy</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ALT</td><td align="left" valign="middle" rowspan="1" colspan="1">Alanine aminotransferase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AST</td><td align="left" valign="middle" rowspan="1" colspan="1">Aspartate aminotransferase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ALP</td><td align="left" valign="middle" rowspan="1" colspan="1">Alkaline phosphatase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LDH</td><td align="left" valign="middle" rowspan="1" colspan="1">Lactate dehydrogenase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LN</td><td align="left" valign="middle" rowspan="1" colspan="1">Laminin</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HA</td><td align="left" valign="middle" rowspan="1" colspan="1">Hyaluronic acid</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PC-III</td><td align="left" valign="middle" rowspan="1" colspan="1">Procollagen III</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IV-C</td><td align="left" valign="middle" rowspan="1" colspan="1">Collagen type IV</td></tr></tbody></array></p></glossary><ref-list><title>References</title><ref id="B1-pharmaceuticals-18-00219"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kisseleva</surname><given-names>T.</given-names></name>
<name><surname>Brenner</surname><given-names>D.</given-names></name>
</person-group><article-title>Molecular and cellular mechanisms of hepatic fibrosis and its regression</article-title><source>Nat. Rev. Gastroenterol. Hepatol.</source><year>2021</year><volume>18</volume><fpage>151</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1038/s41575-020-00372-7</pub-id><pub-id pub-id-type="pmid">33128017</pub-id>
</element-citation></ref><ref id="B2-pharmaceuticals-18-00219"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hammerich</surname><given-names>L.</given-names></name>
<name><surname>Tacke</surname><given-names>F.</given-names></name>
</person-group><article-title>Hepatic inflammatory responses in hepatic fibrosis</article-title><source>Nat. Rev. Gastroenterol. Hepatol.</source><year>2023</year><volume>20</volume><fpage>633</fpage><lpage>646</lpage><pub-id pub-id-type="doi">10.1038/s41575-023-00807-x</pub-id><pub-id pub-id-type="pmid">37400694</pub-id>
</element-citation></ref><ref id="B3-pharmaceuticals-18-00219"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Friedman</surname><given-names>S.L.</given-names></name>
<name><surname>Pinzani</surname><given-names>M.</given-names></name>
</person-group><article-title>hepatic fibrosis 2022: Unmet needs and a blueprint for the future</article-title><source>Hepatology</source><year>2022</year><volume>75</volume><fpage>473</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1002/hep.32285</pub-id><pub-id pub-id-type="pmid">34923653</pub-id>
</element-citation></ref><ref id="B4-pharmaceuticals-18-00219"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tsuchida</surname><given-names>T.</given-names></name>
<name><surname>Friedman</surname><given-names>S.L.</given-names></name>
</person-group><article-title>Mechanisms of hepatic stellate cells activation</article-title><source>Nat. Rev. Gastroenterol. Hepatol.</source><year>2017</year><volume>14</volume><fpage>397</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1038/nrgastro.2017.38</pub-id><pub-id pub-id-type="pmid">28487545</pub-id>
</element-citation></ref><ref id="B5-pharmaceuticals-18-00219"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cai</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Zhou</surname><given-names>Q.</given-names></name>
<name><surname>Yang</surname><given-names>B.</given-names></name>
<name><surname>He</surname><given-names>Q.</given-names></name>
<name><surname>Weng</surname><given-names>Q.</given-names></name>
</person-group><article-title>Intercellular crosstalk of hepatic stellate cells in hepatic fibrosis: New insights into therapy</article-title><source>Pharmacol. Res.</source><year>2020</year><volume>155</volume><fpage>104720</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2020.104720</pub-id><pub-id pub-id-type="pmid">32092405</pub-id>
</element-citation></ref><ref id="B6-pharmaceuticals-18-00219"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Friedman</surname><given-names>S.L.</given-names></name>
</person-group><article-title>Hepatic stellate cells: Protean, multifunctional, and enigmatic cells of the liver</article-title><source>Physiol. Rev.</source><year>2008</year><volume>88</volume><fpage>125</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1152/physrev.00013.2007</pub-id><pub-id pub-id-type="pmid">18195085</pub-id>
</element-citation></ref><ref id="B7-pharmaceuticals-18-00219"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marron</surname><given-names>G.</given-names></name>
<name><surname>Shah</surname><given-names>V.H.</given-names></name>
<name><surname>Gracia-Sancho</surname><given-names>J.</given-names></name>
</person-group><article-title>Sinusoidal communication in hepatic fibrosis and regeneration</article-title><source>J. Hepatol.</source><year>2016</year><volume>65</volume><fpage>608</fpage><lpage>617</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2016.04.018</pub-id><pub-id pub-id-type="pmid">27151183</pub-id>
</element-citation></ref><ref id="B8-pharmaceuticals-18-00219"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Scorletti</surname><given-names>E.</given-names></name>
<name><surname>Carr</surname><given-names>R.M.</given-names></name>
</person-group><article-title>A new perspective on NAFLD: Focusing on lipid droplets</article-title><source>J. Hepatol.</source><year>2022</year><volume>76</volume><fpage>934</fpage><lpage>945</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2021.11.009</pub-id><pub-id pub-id-type="pmid">34793866</pub-id>
</element-citation></ref><ref id="B9-pharmaceuticals-18-00219"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hern&#x000e1;ndez-Gea</surname><given-names>V.</given-names></name>
<name><surname>Friedman</surname><given-names>S.L.</given-names></name>
</person-group><article-title>Autophagy fuels tissue fibrogenesis</article-title><source>Autophagy</source><year>2012</year><volume>8</volume><fpage>849</fpage><lpage>850</lpage><pub-id pub-id-type="doi">10.4161/auto.19947</pub-id><pub-id pub-id-type="pmid">22617442</pub-id>
</element-citation></ref><ref id="B10-pharmaceuticals-18-00219"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
<name><surname>Zhao</surname><given-names>S.</given-names></name>
<name><surname>Yao</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Shao</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>A.</given-names></name>
<name><surname>Zhang</surname><given-names>F.</given-names></name>
<name><surname>Zheng</surname><given-names>S.</given-names></name>
</person-group><article-title>Autophagy regulates turnover of lipid droplets via ROS-dependent Rab25 activation in hepatic stellate cells</article-title><source>Redox Biol.</source><year>2017</year><volume>11</volume><fpage>322</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1016/j.redox.2016.12.021</pub-id><pub-id pub-id-type="pmid">28038427</pub-id>
</element-citation></ref><ref id="B11-pharmaceuticals-18-00219"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zheng</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Macwan</surname><given-names>V.</given-names></name>
<name><surname>Dixon</surname><given-names>C.L.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>S.</given-names></name>
<name><surname>Yu</surname><given-names>Y.</given-names></name>
<name><surname>Xu</surname><given-names>P.</given-names></name>
<name><surname>Sun</surname><given-names>Q.</given-names></name>
<name><surname>Hu</surname><given-names>Q.</given-names></name>
<etal/>
</person-group><article-title>S-acylation of ATGL is required for lipid droplet homoeostasis in hepatocytes</article-title><source>Nat. Metab.</source><year>2024</year><volume>6</volume><fpage>1549</fpage><lpage>1565</lpage><pub-id pub-id-type="doi">10.1038/s42255-024-01085-w</pub-id><pub-id pub-id-type="pmid">39143266</pub-id>
</element-citation></ref><ref id="B12-pharmaceuticals-18-00219"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>He</surname><given-names>J.</given-names></name>
<name><surname>Hong</surname><given-names>B.</given-names></name>
<name><surname>Bian</surname><given-names>M.</given-names></name>
<name><surname>Jin</surname><given-names>H.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Shao</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>F.</given-names></name>
<name><surname>Zheng</surname><given-names>S.</given-names></name>
</person-group><article-title>Docosahexaenoic acid inhibits hepatic stellate cells activation to attenuate hepatic fibrosis in a PPAR&#x003b3;-dependent manner</article-title><source>Int. Immunopharmacol.</source><year>2019</year><volume>75</volume><fpage>105816</fpage><pub-id pub-id-type="doi">10.1016/j.intimp.2019.105816</pub-id><pub-id pub-id-type="pmid">31437794</pub-id>
</element-citation></ref><ref id="B13-pharmaceuticals-18-00219"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shinohara</surname><given-names>S.</given-names></name>
<name><surname>Fujimori</surname><given-names>K.</given-names></name>
</person-group><article-title>Promotion of lipogenesis by PPAR&#x003b3;-activated FXR expression in adipocytes</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2020</year><volume>527</volume><fpage>49</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2020.04.075</pub-id><pub-id pub-id-type="pmid">32446390</pub-id>
</element-citation></ref><ref id="B14-pharmaceuticals-18-00219"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ding</surname><given-names>H.R.</given-names></name>
<name><surname>Wang</surname><given-names>J.L.</given-names></name>
<name><surname>Ren</surname><given-names>H.Z.</given-names></name>
<name><surname>Shi</surname><given-names>X.L.</given-names></name>
</person-group><article-title>Lipometabolism and Glycometabolism in Liver Diseases</article-title><source>Biomed. Res. Int.</source><year>2018</year><volume>2018</volume><elocation-id>1287127</elocation-id><pub-id pub-id-type="doi">10.1155/2018/1287127</pub-id><pub-id pub-id-type="pmid">31205932</pub-id>
</element-citation></ref><ref id="B15-pharmaceuticals-18-00219"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moya-Garzon</surname><given-names>M.D.</given-names></name>
<name><surname>Wang</surname><given-names>M.</given-names></name>
<name><surname>Li</surname><given-names>V.L.</given-names></name>
<name><surname>Lyu</surname><given-names>X.</given-names></name>
<name><surname>Wei</surname><given-names>W.</given-names></name>
<name><surname>Tung</surname><given-names>A.S.-H.</given-names></name>
<name><surname>Raun</surname><given-names>S.H.</given-names></name>
<name><surname>Zhao</surname><given-names>M.</given-names></name>
<name><surname>Coassolo</surname><given-names>L.</given-names></name>
<name><surname>Islam</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>A &#x003b2;-hydroxybutyrate shunt pathway generates anti-obesity ketone metabolites</article-title><source>Cell</source><year>2025</year><volume>188</volume><fpage>175</fpage><lpage>186.e20</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2024.10.032</pub-id><pub-id pub-id-type="pmid">39536746</pub-id>
</element-citation></ref><ref id="B16-pharmaceuticals-18-00219"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>H.</given-names></name>
<name><surname>Zingaro</surname><given-names>V.A.</given-names></name>
<name><surname>Lincoff</surname><given-names>J.</given-names></name>
<name><surname>Tom</surname><given-names>H.</given-names></name>
<name><surname>Oikawa</surname><given-names>S.</given-names></name>
<name><surname>Oses-Prieto</surname><given-names>J.A.</given-names></name>
<name><surname>Edmondson</surname><given-names>Q.</given-names></name>
<name><surname>Seiple</surname><given-names>I.</given-names></name>
<name><surname>Shah</surname><given-names>H.</given-names></name>
<name><surname>Kajimura</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Remodelling of the translatome controls diet and its impact on tumorigenesis</article-title><source>Nature</source><year>2024</year><volume>633</volume><fpage>189</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1038/s41586-024-07781-7</pub-id><pub-id pub-id-type="pmid">39143206</pub-id>
</element-citation></ref><ref id="B17-pharmaceuticals-18-00219"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>C.X.</given-names></name>
<name><surname>Yan</surname><given-names>K.</given-names></name>
<name><surname>Chen</surname><given-names>L.</given-names></name>
<name><surname>Huang</surname><given-names>R.R.</given-names></name>
<name><surname>Bian</surname><given-names>Z.H.</given-names></name>
<name><surname>Wei</surname><given-names>H.R.</given-names></name>
<name><surname>Gu</surname><given-names>X.M.</given-names></name>
<name><surname>Zhao</surname><given-names>Y.Y.</given-names></name>
<name><surname>Liu</surname><given-names>M.C.</given-names></name>
<name><surname>Suo</surname><given-names>C.X.</given-names></name>
<etal/>
</person-group><article-title>Targeting OXCT1-mediated ketone metabolism reprograms macrophages to promote antitumor immunity via CD8+ T cells in hepatocellular carcinoma</article-title><source>J. Hepatol.</source><year>2024</year><volume>81</volume><fpage>690</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2024.05.007</pub-id><pub-id pub-id-type="pmid">38759889</pub-id>
</element-citation></ref><ref id="B18-pharmaceuticals-18-00219"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Puchalska</surname><given-names>P.</given-names></name>
<name><surname>Martin</surname><given-names>S.E.</given-names></name>
<name><surname>Huang</surname><given-names>X.</given-names></name>
<name><surname>Lengfeld</surname><given-names>J.E.</given-names></name>
<name><surname>Daniel</surname><given-names>B.</given-names></name>
<name><surname>Graham</surname><given-names>M.J.</given-names></name>
<name><surname>Han</surname><given-names>X.</given-names></name>
<name><surname>Nagy</surname><given-names>L.</given-names></name>
<name><surname>Patti</surname><given-names>G.J.</given-names></name>
<name><surname>Crawford</surname><given-names>P.A.</given-names></name>
</person-group><article-title>Hepatocyte-Macrophage Acetoacetate Shuttle Protects against Tissue Fibrosis</article-title><source>Cell Metab.</source><year>2019</year><volume>29</volume><fpage>383</fpage><lpage>398.e7</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2018.10.015</pub-id><pub-id pub-id-type="pmid">30449686</pub-id>
</element-citation></ref><ref id="B19-pharmaceuticals-18-00219"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liao</surname><given-names>Y.J.</given-names></name>
<name><surname>Wang</surname><given-names>Y.H.</given-names></name>
<name><surname>Wu</surname><given-names>C.Y.</given-names></name>
<name><surname>Hsu</surname><given-names>F.Y.</given-names></name>
<name><surname>Chien</surname><given-names>C.Y.</given-names></name>
<name><surname>Lee</surname><given-names>Y.C.</given-names></name>
</person-group><article-title>Ketogenic Diet Enhances the Cholesterol Accumulation in Liver and Augments the Severity of CCl<sub>4</sub> and TAA-Induced hepatic fibrosis in Mice</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>2934</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22062934</pub-id><pub-id pub-id-type="pmid">33805788</pub-id>
</element-citation></ref><ref id="B20-pharmaceuticals-18-00219"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Walther</surname><given-names>T.C.</given-names></name>
<name><surname>Chung</surname><given-names>J.</given-names></name>
<name><surname>Farese</surname><given-names>R.V.</given-names><suffix>Jr.</suffix></name>
</person-group><article-title>Lipid Droplet Biogenesis</article-title><source>Annu. Rev. Cell Dev. Biol.</source><year>2017</year><volume>33</volume><fpage>491</fpage><lpage>510</lpage><pub-id pub-id-type="doi">10.1146/annurev-cellbio-100616-060608</pub-id><pub-id pub-id-type="pmid">28793795</pub-id>
</element-citation></ref><ref id="B21-pharmaceuticals-18-00219"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Menendez</surname><given-names>J.A.</given-names></name>
<name><surname>Lupu</surname><given-names>R.</given-names></name>
</person-group><article-title>Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis</article-title><source>Nat. Rev. Cancer</source><year>2007</year><volume>7</volume><fpage>763</fpage><lpage>777</lpage><pub-id pub-id-type="doi">10.1038/nrc2222</pub-id><pub-id pub-id-type="pmid">17882277</pub-id>
</element-citation></ref><ref id="B22-pharmaceuticals-18-00219"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>L.</given-names></name>
<name><surname>Ning</surname><given-names>X.</given-names></name>
<name><surname>Wei</surname><given-names>L.</given-names></name>
<name><surname>Zhou</surname><given-names>Y.</given-names></name>
<name><surname>Zhao</surname><given-names>L.</given-names></name>
<name><surname>Ma</surname><given-names>F.</given-names></name>
<name><surname>Bai</surname><given-names>M.</given-names></name>
<name><surname>Yang</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>D.</given-names></name>
<name><surname>Sun</surname><given-names>S.</given-names></name>
</person-group><article-title>Twist1 downregulation of PGC-1&#x003b1; decreases fatty acid oxidation in tubular epithelial cells, leading to kidney fibrosis</article-title><source>Theranostics</source><year>2022</year><volume>12</volume><fpage>3758</fpage><lpage>3775</lpage><pub-id pub-id-type="doi">10.7150/thno.71722</pub-id><pub-id pub-id-type="pmid">35664054</pub-id>
</element-citation></ref><ref id="B23-pharmaceuticals-18-00219"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lynes</surname><given-names>M.D.</given-names></name>
<name><surname>Leiria</surname><given-names>L.O.</given-names></name>
<name><surname>Lundh</surname><given-names>M.</given-names></name>
<name><surname>Bartelt</surname><given-names>A.</given-names></name>
<name><surname>Shamsi</surname><given-names>F.</given-names></name>
<name><surname>Huang</surname><given-names>T.L.</given-names></name>
<name><surname>Takahashi</surname><given-names>H.</given-names></name>
<name><surname>Hirshman</surname><given-names>M.F.</given-names></name>
<name><surname>Schlein</surname><given-names>C.</given-names></name>
<name><surname>Lee</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>The cold-induced lipokine 12,13-diHOME promotes fatty acid transport into brown adipose tissue</article-title><source>Nat. Med.</source><year>2017</year><volume>23</volume><fpage>631</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.1038/nm.4297</pub-id><pub-id pub-id-type="pmid">28346411</pub-id>
</element-citation></ref><ref id="B24-pharmaceuticals-18-00219"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>S.</given-names></name>
<name><surname>Ren</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Lei</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>M.</given-names></name>
<name><surname>Wang</surname><given-names>F.</given-names></name>
<name><surname>Cheng</surname><given-names>S.</given-names></name>
<name><surname>Ying</surname><given-names>J.</given-names></name>
<name><surname>Ding</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
</person-group><article-title>Knockdown of the Clock gene in the liver aggravates MASLD in mice via inhibiting lipophagy</article-title><source>Mol. Cell Biochem.</source><year>2024</year><pub-id pub-id-type="doi">10.1007/s11010-024-05109-7</pub-id></element-citation></ref><ref id="B25-pharmaceuticals-18-00219"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Q.</given-names></name>
<name><surname>Ni</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Jiang</surname><given-names>R.</given-names></name>
<name><surname>Xu</surname><given-names>J.</given-names></name>
<name><surname>Yang</surname><given-names>H.</given-names></name>
<name><surname>Hu</surname><given-names>Y.</given-names></name>
<name><surname>Qiu</surname><given-names>J.</given-names></name>
<name><surname>Pu</surname><given-names>L.</given-names></name>
<name><surname>Tang</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>HIF-1&#x003b1;-induced expression of m6A reader YTHDF1 drives hypoxia-induced autophagy and malignancy of hepatocellular carcinoma by promoting ATG2A and ATG14 translation</article-title><source>Signal Transduct. Target. Ther.</source><year>2021</year><volume>6</volume><fpage>76</fpage><pub-id pub-id-type="doi">10.1038/s41392-020-00453-8</pub-id><pub-id pub-id-type="pmid">33619246</pub-id>
</element-citation></ref><ref id="B26-pharmaceuticals-18-00219"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>T.</given-names></name>
<name><surname>Qu</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Xu</surname><given-names>D.</given-names></name>
<name><surname>Sheng</surname><given-names>M.</given-names></name>
<name><surname>Lin</surname><given-names>Y.</given-names></name>
<name><surname>Ke</surname><given-names>M.</given-names></name>
<name><surname>Song</surname><given-names>C.</given-names></name>
<name><surname>Xia</surname><given-names>Q.</given-names></name>
<name><surname>Jiang</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>The macrophage STING-YAP axis controls hepatic steatosis by promoting the autophagic degradation of lipid droplets</article-title><source>Hepatology</source><year>2024</year><volume>80</volume><fpage>1169</fpage><lpage>1183</lpage><pub-id pub-id-type="doi">10.1097/HEP.0000000000000638</pub-id><pub-id pub-id-type="pmid">37870294</pub-id>
</element-citation></ref><ref id="B27-pharmaceuticals-18-00219"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sato</surname><given-names>Y.</given-names></name>
<name><surname>Murase</surname><given-names>K.</given-names></name>
<name><surname>Kato</surname><given-names>J.</given-names></name>
<name><surname>Kobune</surname><given-names>M.</given-names></name>
<name><surname>Sato</surname><given-names>T.</given-names></name>
<name><surname>Kawano</surname><given-names>Y.</given-names></name>
<name><surname>Takimoto</surname><given-names>R.</given-names></name>
<name><surname>Takada</surname><given-names>K.</given-names></name>
<name><surname>Miyanishi</surname><given-names>K.</given-names></name>
<name><surname>Matsunaga</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone</article-title><source>Nat. Biotechnol.</source><year>2008</year><volume>26</volume><fpage>431</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1038/nbt1396</pub-id><pub-id pub-id-type="pmid">18376398</pub-id>
</element-citation></ref><ref id="B28-pharmaceuticals-18-00219"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tao</surname><given-names>J.</given-names></name>
<name><surname>Wu</surname><given-names>Z.</given-names></name>
<name><surname>Liang</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Tang</surname><given-names>M.</given-names></name>
<name><surname>Huang</surname><given-names>S.</given-names></name>
<name><surname>Jiang</surname><given-names>F.</given-names></name>
<name><surname>Zhou</surname><given-names>G.</given-names></name>
<name><surname>Guo</surname><given-names>L.</given-names></name>
<name><surname>Yuan</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Lhx2 specifically expressed in hepatic stellate cells promotes liver regeneration and inhibits hepatic fibrosis</article-title><source>Hepatology</source><year>2024</year><pub-id pub-id-type="doi">10.1097/HEP.0000000000001201</pub-id></element-citation></ref><ref id="B29-pharmaceuticals-18-00219"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wagner</surname><given-names>N.</given-names></name>
<name><surname>Wagner</surname><given-names>K.D.</given-names></name>
</person-group><article-title>Recent Insights into the Role of PPARs in Disease</article-title><source>Cells</source><year>2023</year><volume>12</volume><elocation-id>1572</elocation-id><pub-id pub-id-type="doi">10.3390/cells12121572</pub-id><pub-id pub-id-type="pmid">37371042</pub-id>
</element-citation></ref><ref id="B30-pharmaceuticals-18-00219"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Michalik</surname><given-names>L.</given-names></name>
<name><surname>Wahli</surname><given-names>W.</given-names></name>
</person-group><article-title>PPARs Mediate Lipid Signaling in Inflammation and Cancer</article-title><source>PPAR Res.</source><year>2008</year><volume>2008</volume><fpage>134059</fpage><pub-id pub-id-type="doi">10.1155/2008/134059</pub-id><pub-id pub-id-type="pmid">19125181</pub-id>
</element-citation></ref><ref id="B31-pharmaceuticals-18-00219"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ballav</surname><given-names>S.</given-names></name>
<name><surname>Biswas</surname><given-names>B.</given-names></name>
<name><surname>Sahu</surname><given-names>V.K.</given-names></name>
<name><surname>Ranjan</surname><given-names>A.</given-names></name>
<name><surname>Basu</surname><given-names>S.</given-names></name>
</person-group><article-title>PPAR-&#x003b3; Partial Agonists in Disease-Fate Decision with Special Reference to Cancer</article-title><source>Cells</source><year>2022</year><volume>11</volume><elocation-id>3215</elocation-id><pub-id pub-id-type="doi">10.3390/cells11203215</pub-id><pub-id pub-id-type="pmid">36291082</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceuticals-18-00219-f001"><label>Figure 1</label><caption><p>The ketone body AcAc but not BHB inhibits HSC activation. (<bold>A</bold>,<bold>B</bold>) The MTT assay was used to determine the cell viability of LX-2 after AcAc and BHB, respectively (n = 5 per group). (<bold>C</bold>) The mRNA levels of <italic toggle="yes">&#x003b1;-SMA</italic> and <italic toggle="yes">fibronectin</italic> in LX-2 cells treated with BHB were determined by RT-qPCR (n = 3 per group). (<bold>D</bold>) The mRNA levels of <italic toggle="yes">&#x003b1;-SMA</italic> and <italic toggle="yes">fibronectin</italic> in LX-2 cells treated with AcAc were determined by RT-qPCR (n = 3 per group). (<bold>E</bold>) Protein levels of &#x003b1;-SMA and fibronectin in BHB-treated LX-2 cells were determined by Western blot analysis (n = 3 per group). (<bold>F</bold>) Protein levels of &#x003b1;-SMA and fibronectin in LX-2 cells treated with AcAc were determined by Western blot analysis (n = 3 per group). Bars represent the mean &#x000b1; standard error of the mean (SEM); * <italic toggle="yes">p</italic> &#x0003c; 0.05, ** <italic toggle="yes">p</italic> &#x0003c; 0.01, *** <italic toggle="yes">p</italic> &#x0003c; 0.001, **** <italic toggle="yes">p</italic> &#x0003c; 0.0001 vs. control.</p></caption><graphic xlink:href="pharmaceuticals-18-00219-g001" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00219-f002"><label>Figure 2</label><caption><p>AcAc alleviated HF. (<bold>A</bold>) Following the experiment, the livers of each animal were removed and imaged to determine the form of the liver. Liver sections were stained with hematoxylin and eosin (H&#x00026;E), Sirius Red, and Masson at 4 &#x003bc;m thickness; scale bar is 50 &#x003bc;m for histopathology research (n = 6 per group). (<bold>B</bold>) Determination of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), laminin (LN), hyaluronic acid (HA), procollagen III (PC-III), and collagen type IV (IV-C) in mouse serum by ELISA (n = 6 per group). (<bold>C</bold>) Detection of protein expression levels of &#x003b1;-smooth muscle actin (&#x003b1;-SMA) and fibronectin, markers of hepatic stellate cells activation, in mouse liver tissue by Western blot analysis (n = 3 per group). Bars represent the mean &#x000b1; standard error of the mean (SEM). ** <italic toggle="yes">p</italic> &#x0003c; 0.01, *** <italic toggle="yes">p</italic> &#x0003c; 0.001 vs. vehicle, <sup>#</sup>
<italic toggle="yes">p</italic> &#x0003c; 0.05, <sup>##</sup>
<italic toggle="yes">p</italic> &#x0003c; 0.01, <sup>###</sup>
<italic toggle="yes">p</italic> &#x0003c; 0.001 vs. CCl<sub>4</sub>.</p></caption><graphic xlink:href="pharmaceuticals-18-00219-g002" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00219-f003"><label>Figure 3</label><caption><p>AcAc increased the content of lipid droplets in HSCs. (<bold>A</bold>) Lipid droplet levels of LX-2 cells were detected by Oil Red O staining and Nile Red staining. Scale bars are 20&#x02009;&#x000b5;m (n = 3 per group). (<bold>B</bold>&#x02013;<bold>D</bold>) Detection of TG (<bold>B</bold>), TC (<bold>C</bold>), and RET (<bold>D</bold>) levels of LX-2 cells treated with different doses of AcAc by TG, TC, and RET kits (n = 5 per group). (<bold>E</bold>) RT-qPCR was used to measure mRNA levels of lipid metabolism in LX-2 cells treated with AcAc. Lipogenesis: <italic toggle="yes">ACACa</italic>, <italic toggle="yes">SREBP1</italic>, <italic toggle="yes">FASN</italic>, <italic toggle="yes">PPAR&#x003b3;</italic>, <italic toggle="yes">SCD1</italic>; fatty acid oxidation: <italic toggle="yes">CPT1</italic>, <italic toggle="yes">ACOX1</italic>, <italic toggle="yes">MCAD</italic>, <italic toggle="yes">PPAR&#x003b1;</italic>; fatty acid uptake: <italic toggle="yes">ATGL</italic>, <italic toggle="yes">FATP1</italic>, <italic toggle="yes">CD36</italic>; lipid droplet autophagy: <italic toggle="yes">ATG2A</italic>, <italic toggle="yes">RAB7</italic>, <italic toggle="yes">PLIN2</italic> (n = 3 per group). Bars indicate the mean &#x000b1; SEM. * <italic toggle="yes">p</italic> &#x0003c; 0.05, ** <italic toggle="yes">p</italic> &#x0003c; 0.01, *** <italic toggle="yes">p</italic> &#x0003c; 0.001, **** <italic toggle="yes">p</italic> &#x0003c; 0.0001 vs. control.</p></caption><graphic xlink:href="pharmaceuticals-18-00219-g003" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00219-f004"><label>Figure 4</label><caption><p>Interference of PPAR&#x003b3; reversed the inhibition of HSC activation by AcAc. (<bold>A</bold>) Protein expression of PPAR&#x003b3; in LX-2 after treatment with different concentrations of AcAc was detected using Western blot analysis (n = 3 per group). (<bold>B</bold>,<bold>C</bold>) The interference efficiency of siPPAR&#x003b3; was verified by RT-qPCR and Western blot analysis (n = 3 per group). (<bold>D</bold>) RT-qPCR was used to detect the mRNA levels of <italic toggle="yes">&#x003b1;-SMA</italic> and <italic toggle="yes">fibronectin</italic> in LX-2 cells transfected with siPPAR&#x003b3; for 24 h after AcAc treatment (n = 3 per group). (<bold>E</bold>) Western blot analysis was used to detect protein levels of &#x003b1;-SMA and fibronectin in LX-2 cells transfected with siPPAR&#x003b3; for 24 h after AcAc treatment (n = 3 per group). (<bold>F</bold>) The content of lipid droplets in LX-2 was detected using Nile Red staining and Oil Red O staining in AcAc-treated LX-2 cells for 24 h and then transfected with siPPAR&#x003b3; for 24 h (n = 3 per group). (<bold>G</bold>&#x02013;<bold>I</bold>) The levels of TC, TG, and RET in LX-2 cells were determined by treating LX-2 cells with AcAc for 24 h and then transfecting them with siPPAR&#x003b3; for 24 h (n = 3 per group). Bars represent the mean &#x000b1; standard error of the mean (SEM). * <italic toggle="yes">p</italic> &#x0003c; 0.05, ** <italic toggle="yes">p</italic> &#x0003c; 0.01, *** <italic toggle="yes">p</italic> &#x0003c; 0.001 vs. control, <sup>##</sup>
<italic toggle="yes">p</italic> &#x0003c; 0.01, <sup>###</sup>
<italic toggle="yes">p</italic> &#x0003c; 0.001 vs. siPPAR&#x003b3;.</p></caption><graphic xlink:href="pharmaceuticals-18-00219-g004" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00219-f005"><label>Figure 5</label><caption><p>Interference of PPAR&#x003b3; reversed the anti-fibrotic effect of AcAc. (<bold>A</bold>) Following the experiment, the livers of each animal were removed and imaged to determine the form of the liver. Liver sections were stained with hematoxylin and eosin (H&#x00026;E), Sirius Red, and Masson at 4 &#x003bc;m thickness; scale bar is 50 &#x003bc;m for histopathology research (n = 6 per group). (<bold>B</bold>) Determination of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), Lactate dehydrogenase (LDH), laminin (LN), hyaluronic acid (HA), procollagen III (PC-III), and collagen type IV (IV-C) in mouse serum by ELISA (n = 6 per group). (<bold>C</bold>) Protein expression levels of &#x003b1;-SMA, fibronectin, and PPAR&#x003b3; in mouse liver tissues detected using Western blot analysis (n = 3 per group). Bars represent the mean &#x000b1; standard error of the mean (SEM). * <italic toggle="yes">p</italic> &#x0003c; 0.05, *** <italic toggle="yes">p</italic> &#x0003c; 0.001 vs. vehicle, <sup>#</sup>
<italic toggle="yes">p</italic> &#x0003c; 0.05, <sup>##</sup>
<italic toggle="yes">p</italic> &#x0003c; 0.01, <sup>###</sup>
<italic toggle="yes">p</italic> &#x0003c; 0.001 vs. CCl<sub>4</sub>.</p></caption><graphic xlink:href="pharmaceuticals-18-00219-g005" position="float"/></fig><table-wrap position="float" id="pharmaceuticals-18-00219-t001"><object-id pub-id-type="pii">pharmaceuticals-18-00219-t001_Table 1</object-id><label>Table 1</label><caption><p>Sequence of primers for RT-qPCR.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gene</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">5&#x02032; Forward Primer (5&#x02032;&#x02013;3&#x02032;)</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">3&#x02032; Reverse Primer (5&#x02032;&#x02013;3&#x02032;)</th></tr></thead><tbody><tr><td colspan="3" align="left" valign="middle" rowspan="1">Human</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">&#x003b1;-SMA</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">CCGACCGAATGCAGAAGGA</td><td align="left" valign="middle" rowspan="1" colspan="1">ACAGAGTATTTGCGCTCCGGA</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Fibronectin</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">AGGAAGCCGAGGTTTTAACTG</td><td align="left" valign="middle" rowspan="1" colspan="1">AGGACGCTCATAAGTCACC</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">GADPH</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">ATTCCACCCATGGCAAATTCC</td><td align="left" valign="middle" rowspan="1" colspan="1">GACTCCACGACGTACTCAGC</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">PPAR&#x003b3;</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">CATAAAGTCCTTCCCGCTGA</td><td align="left" valign="middle" rowspan="1" colspan="1">TCTGTGATCTCCTGCACAGC</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">ACACa</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">TTCTGCACACGTTCCTTGTC</td><td align="left" valign="middle" rowspan="1" colspan="1">TGCAGCAGCAACACTGAAAT</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">SREBP1c</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">TGAGGACAGCAAGGCAAAG</td><td align="left" valign="middle" rowspan="1" colspan="1">CAGGACAGGCAGAGGAAGAC</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">FASN</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">GTCCACCAGCAACATCAGC</td><td align="left" valign="middle" rowspan="1" colspan="1">GTTCTCCAGCAAGCCATCTC</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">PGC-1</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">TCCTTTGGGGTCTTTGAGAA</td><td align="left" valign="middle" rowspan="1" colspan="1">GGCACGCAATCCTATTCATT</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">CPT1a</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">GCACATCGTCGTGTACCATC</td><td align="left" valign="middle" rowspan="1" colspan="1">AATAGGCCTGACGACACCTG</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">ACOX1</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">CTGTGAGGCACCAGTCTGAA</td><td align="left" valign="middle" rowspan="1" colspan="1">AGGTGAAAGCCTTCAGTCCA</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">MCAD</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">ACAGGGGTTCAGACTGCTATT</td><td align="left" valign="middle" rowspan="1" colspan="1">TCCTCCGTTGGTTATCCACAT</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">FATP1</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">ACGCGATATACCAGGAGCTG</td><td align="left" valign="middle" rowspan="1" colspan="1">ATCTTGAAGGTGCCTGTGGT</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">CD36</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">ACGCTGAGGACAACACAGTCT</td><td align="left" valign="middle" rowspan="1" colspan="1">GCCACAGCCAGATTGAGAAC</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">FAbP1</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">GCTGGGTCCAAAGTGATCCA</td><td align="left" valign="middle" rowspan="1" colspan="1">TGTCACCTTCCAACTGAACCA</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">ATGL</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">CAACGCCACGCACATCTAC</td><td align="left" valign="middle" rowspan="1" colspan="1">CAATGAACTTGGCACCAGCC</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">SCD1</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">TCTAGCTCCTATACCACCACCA</td><td align="left" valign="middle" rowspan="1" colspan="1">TCGTCTCCAACTTATCTCCTCC</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">RAB7</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">GTGTTGCTGAAGGTTATCATCCT</td><td align="left" valign="middle" rowspan="1" colspan="1">GCTCCTATTGTGGCTTTGTACTG</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">PLIN2</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">TTGCAGTTGCCAATACCTATGC</td><td align="left" valign="middle" rowspan="1" colspan="1">CCAGTCACAGTAGTCGTCACA</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">si<italic toggle="yes">PPAR&#x003b3;</italic></td><td align="left" valign="middle" rowspan="1" colspan="1">GGAUGCAAGGGUUUCUUCCTT</td><td align="left" valign="middle" rowspan="1" colspan="1">GGAAGAAACCCUUGCAUCCTT</td></tr><tr><td colspan="3" align="left" valign="middle" rowspan="1">Mouse</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GADPH</td><td align="left" valign="middle" rowspan="1" colspan="1">GGAGAGTGTTTCCTCGTCCC</td><td align="left" valign="middle" rowspan="1" colspan="1">ACTGTGCCGTTGAATTTGCC</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">&#x003b1;-SMA</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">GTACCACCATGTACCCAGGC</td><td align="left" valign="middle" rowspan="1" colspan="1">GCTGGAAGGTAGACAGCGAA</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Fibronectin</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">ATGTGGACCCCTCCTGATAGT</td><td align="left" valign="middle" rowspan="1" colspan="1">GCCCAGTGATTTCAGCAAAGG</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">PPAR&#x003b3;</italic>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GGAAGACCACTCGCATTCCTT</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GTAATCAGCAACCATTGGGTCA</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceuticals-18-00219-t002"><object-id pub-id-type="pii">pharmaceuticals-18-00219-t002_Table 2</object-id><label>Table 2</label><caption><p>Antibodies used in this study.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Antibodies</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Host</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Dilution</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Catalogue</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Company</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">anti-&#x003b2;-Actin</td><td align="left" valign="middle" rowspan="1" colspan="1">Rabbit pAb</td><td align="left" valign="middle" rowspan="1" colspan="1">1:2000&#x02013;1:3000</td><td align="left" valign="middle" rowspan="1" colspan="1">66009-1-AP</td><td align="left" valign="middle" rowspan="1" colspan="1">Proteintech</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">anti-<italic toggle="yes">&#x003b1;</italic>-SMA</td><td align="left" valign="middle" rowspan="1" colspan="1">Rabbit pAb</td><td align="left" valign="middle" rowspan="1" colspan="1">1:1000&#x02013;1:4000</td><td align="left" valign="middle" rowspan="1" colspan="1">ab32575</td><td align="left" valign="middle" rowspan="1" colspan="1">Abcam</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">anti-Fibronectin</td><td align="left" valign="middle" rowspan="1" colspan="1">Rabbit pAb</td><td align="left" valign="middle" rowspan="1" colspan="1">1:1000&#x02013;1:4000</td><td align="left" valign="middle" rowspan="1" colspan="1">ab2413</td><td align="left" valign="middle" rowspan="1" colspan="1">Abcam</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">anti-PPAR&#x003b3;</td><td align="left" valign="middle" rowspan="1" colspan="1">Rabbit pAb</td><td align="left" valign="middle" rowspan="1" colspan="1">1:500&#x02013;1:3000</td><td align="left" valign="middle" rowspan="1" colspan="1">A6981</td><td align="left" valign="middle" rowspan="1" colspan="1">ABclonal</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">anti-rabbit IgG</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rabbit pAb</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1:500&#x02013;1:2000</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SA00001-2</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ABclonal</td></tr></tbody></table></table-wrap></floats-group></article>